Aurinia (AUPH) CMO awarded new stock options and share grant

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. reported that SVP and Chief Medical Officer Greg Keenan received new equity awards on February 27, 2026. He was granted stock options for 67,870 shares at an exercise price of $0, increasing his option holdings to 67,870 shares.

He also acquired 40,586 shares of common stock as a grant or award at a stated price of $0, bringing his directly held common shares to 162,518. Footnotes explain that related performance rights vest in tranches based on share price targets and time-based vesting schedules.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Keenan Greg

Role SVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	67,870	$0.00	--
Grant/Award	Common Stock	40,586	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 67,870 shares (Direct); Common Stock — 162,518 shares (Direct)

Footnotes (1)

1. Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keenan Greg

(Last) (First) (Middle)

#140, 14315 - 118 AVENUE

(Street)

EDMONTON A0 T5L 4S6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		40,586(1)	A	$0	162,518	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.97	02/27/2026		A		67,870		(2)	02/27/2036	Common Stock	67,870	$0	67,870	D

Explanation of Responses:

1. Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.

2. One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

Remarks:

	/s/ Greg Keenan, M.D.	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Aurinia Pharmaceuticals (AUPH) report for Greg Keenan?

Aurinia Pharmaceuticals reported that SVP and Chief Medical Officer Greg Keenan received two equity awards on February 27, 2026. He was granted stock options and a separate common stock award, both recorded as acquisitions rather than open-market purchases or sales.

How many stock options were granted to Aurinia SVP Greg Keenan in this Form 4?

Greg Keenan received an option grant covering 67,870 shares of Aurinia Pharmaceuticals common stock. One-third of these options vest 12 months after the grant date, with the remaining two-thirds vesting in 24 equal monthly installments thereafter, subject to continued service conditions.

What common stock award did Aurinia’s Chief Medical Officer receive according to the Form 4?

The Form 4 shows Greg Keenan acquired 40,586 shares of Aurinia common stock as a grant or award at a stated price of $0. After this transaction, his directly held common stock position increased to 162,518 shares, according to the reported post-transaction balance.

How do the performance rights mentioned in the Aurinia Form 4 vest?

Each performance right represents a contingent right to receive one Aurinia common share. The performance rights vest in four tranches as the share price reaches progressively higher targets, with a one-year retention period following achievement for each tranche, adding performance and time-based conditions.

Are Greg Keenan’s Aurinia transactions open-market buys or equity awards?

The transactions are classified as grants or awards, not open-market buys. Both the option grant and the common stock acquisition carry a transaction code “A” for award, with a reported price of $0 per share, indicating compensation-related equity rather than market purchases.